Ajinomoto Althea gets US patent for fast, industrial-scale antibody crystallization method

By Gareth Macdonald

- Last updated on GMT

iStock/rep0rter
iStock/rep0rter
Ajinomoto Althea has been granted a US patent for a whole antibody crystallization method that is faster at producing stable, biologically-active crystals than current techniques.

The patented method​ – dubbed the Crystalomics formulation technology – uses whole antibody crystals to seed crystallization according to Don Paul Kovarcik, who told us the CMO uses an iterative process to identify the optimum conditions to accelerate the process.

Althea typically screens over a thousand crystallization conditions. Variables include the types and concentrations of salts, precipitants and buffers as well as combinations of pH and temperature.

The best crystallization conditions use pharmaceutically acceptable ingredients and are selected to give the highest yield of uniform crystals of a narrow size range in a relatively short amount of time, usually less than 24 hours​.”

This is much faster than current antibody crystallization process, which can take weeks according to Kovarcik.

Targeted approach

Crystallization is often described as being more of an art than a science because choosing the optimum conditions for a successful reaction conducted using established methods requires a combination of luck and judgement.

Ajinomoto Althea’s method differs according to Kovarcik, who said: “We are taking a more targeted approachby doing a complete characterization of the molecule. The more information we have upfront, the more specific/targeted we can get with our screen. 

There are an infinite number of excipients, additives and combinations thereof, so the ability to narrow down the possibilities greatly improves efficiency.  In the end each molecule is different, so there is no formula that will necessarily give good results​.”

The method is intended for use in the crystallisation of whole antibodies or fragments at commercial-scaleKovarcik said, adding that: “Althea has successfully crystalized over 100 molecules including antibodies, hormones, enzymes, peptides, and nucleic acids from human, animal and microbial sources​.”

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars